Hereditary Alpha Tryptasemia
Elevated baseline tryptase is no longer a curiosity — it is a recognized trait that shapes mast cell, connective tissue, and autonomic disease. Most clinicians have not caught up.
What we mean when we say HαT.
Hereditary Alpha Tryptasemia (HαT) is an autosomal dominant genetic trait caused by extra copies of the TPSAB1 gene encoding alpha-tryptase. It produces elevated baseline serum tryptase levels and a recognized clinical constellation including flushing, GI symptoms, dysautonomia, joint hypermobility, anxiety, and severe reactions to insect stings and other triggers.
HαT was first formally described in 2016 and remains under-recognized in routine practice. It is now estimated to be present in roughly 5–7% of the general population, and at significantly higher rates among patients with diagnosed MCAS, mastocytosis, idiopathic anaphylaxis, hEDS, and POTS.
The diagnosis is made via specific genetic testing for TPSAB1 copy number. Recognition matters because it changes prognosis, risk stratification for severe reactions, and approach to comorbid management.
Estimated 5–7% of the general population. Significantly enriched in MCAS, mastocytosis, hEDS, POTS, and idiopathic anaphylaxis populations.
Why HαT gets missed.
Hereditary Alpha Tryptasemia (HαT) is a recently characterized genetic trait that explains a clinical picture many patients have carried for years without recognition. The trait is invisible to most clinicians because the specific testing required to identify it is not part of routine evaluations.
- 01Baseline tryptase is rarely measured outside of mastocytosis workups. Even when elevated tryptase is identified, it is rarely followed with the TPSAB1 copy number testing that confirms HαT.
- 02The clinical phenotype — flushing, GI symptoms, joint hypermobility, dysautonomia, anxiety, severe insect-sting reactions — is attributed to whichever specialist sees the patient first. Allergists see the reactions, rheumatology sees the hypermobility, GI sees the symptoms, and no one connects them.
- 03HαT is enriched among patients diagnosed with MCAS, mastocytosis, hEDS, POTS, and idiopathic anaphylaxis. When HαT is identified, it explains the severity and clustering of these conditions and changes management — but the testing is rarely done.
- 04Risk stratification for severe reactions, including anaphylaxis from insect stings and certain medications, is different in HαT-positive patients. Without the diagnosis, the heightened risk goes unaddressed.
The Ternary Health approach to Hereditary Alpha Tryptasemia.
Confirm or rule out HαT through the appropriate testing pathway — baseline tryptase, TPSAB1 copy number genetic testing, and family member evaluation where pedigree work is informative.
Characterize the phenotype specifically. HαT is associated with a recognized constellation of findings, but expression varies. Mapping which features are present and which are absent shapes both prognosis and management.
Evaluate the overlap with MCAS, mastocytosis, hEDS, POTS, and idiopathic anaphylaxis. HαT modifies the severity and presentation of each, and recognition changes treatment selection across all of them.
Build the risk-stratified management plan — insect sting precautions, medication and procedural clearance, mast cell stabilizer considerations — calibrated to HαT-positive physiology.
The Ternary Signal Library for HαT.
Our Signal Library for HαT codifies the specific patterns that matter — tryptase and genetic findings, mediator and allergic history, connective tissue and autonomic phenotype, and overlap with mast cell disorders. Your case is mapped against these signals; each present signal is identified and prioritized for your presentation.
- —Baseline serum tryptase — multiple measurements where available
- —TPSAB1 copy number genetic testing
- —Family member tryptase screening where pedigree informative
- —Acute-versus-baseline tryptase ratio in reaction episodes
- —Tryptase trend over time
- —Reaction history — triggers, severity, treatment response
- —Insect sting reaction documentation — heightened HαT risk
- —Idiopathic anaphylaxis episodes
- —Medication reaction history — opioid, anesthetic, contrast
- —Mediator panel where MCAS evaluation in scope
- —Hypermobility — Beighton score, generalized joint mobility
- —Skin findings — hyperextensibility, atrophic scarring
- —Orthostatic intolerance and POTS criteria evaluation
- —GI dysmotility and irritable bowel pattern
- —Anxiety and mood pattern within the HαT phenotype
- —MCAS consensus criteria evaluation
- —Systemic mastocytosis screening — KIT mutation, marrow considerations
- —Multi-system mediator-release symptom pattern
- —Cutaneous mastocytosis findings if present
- —Family history of mast cell disorders
How a HαT case moves through our workflow.
Our nine-stage workflow is the same for every engagement. What changes per condition is the content at each stage — the records we pull, the signals we apply, the specialists we map, the pathways we evaluate. Below, how your case specifically would move through each stage.
What you receive.
- —A written case synthesis confirming HαT status and characterizing the specific phenotype in your case
- —Integration of tryptase, genetic, allergic, and comorbid findings into a single view
- —Risk-stratified anaphylaxis and reaction management plan including insect sting protocols
- —Medication and procedural clearance protocols calibrated to HαT physiology
- —Specialist identification for HαT-experienced allergy/immunology and any indicated comorbid workup
- —A written action plan and follow-up support as you implement it
What a Precision Deep Dive provides for HαT.
A Ternary Health Precision Deep Dive for HαT evaluates testing strategy, characterizes the phenotype, maps overlap with MCAS, hEDS, POTS, and anaphylaxis history, and provides risk stratification and management guidance specific to the HαT-positive population.
See the published sample reports · read the Ternary Method
What we look for alongside HαT.
Patients with Hereditary Alpha Tryptasemia frequently present with one or more of the following. Ternary reports evaluate the full picture rather than the condition in isolation.
- Mast Cell Activation Syndrome
- Systemic mastocytosis
- Hypermobile Ehlers-Danlos Syndrome
- Postural Orthostatic Tachycardia Syndrome
- Idiopathic anaphylaxis
What prospective Hereditary Alpha Tryptasemia clients ask most.
Three ways to engage Ternary on HαT.
From a free starting point to a full personalized action plan — three tiers, one methodology, all tailored to HαT.
Free Brief
A 3–5 page personalized starting point on your condition. Most relevant labs, specialist categories, first decisions worth pursuing. No charge.
Generated instantly, no charge.
Get a free Brief→Launchpad
A research-based preparedness guide. Current literature, realistic prognosis, test and treatment categories worth exploring, and a checklist of what you might consider to better manage and understand your condition.
Delivered in 3–5 business days
Start a Launchpad→Precision Deep Dive
A vigorously researched and highly personalized action plan: the specialists and centers of excellence worth considering, evidence-graded options, and a prioritized set of questions to raise — all curated for your specific condition and lifestyle, for you and your physicians to weigh together. The plan includes 30 days of follow-up support and tailored insights into how best to navigate your situation now and in the future.
September 2026 cohort
Apply for a Deep Dive→See exactly what you receive.
A composite sample illustrating the structure and depth of every Ternary Health Precision Deep Dive. Same universal 17-section format used for HαT — drawn from four research-validated patient profiles across four conditions.
Every Ternary engagement produces a report with the same architecture: client profile, applied methodology, signal analysis, lab and genetic findings, imaging synthesis, disease model, intervention prioritization, specialist pathway, staged medical therapy, 90-day roadmap, and monitoring cadence. The composite shows you exactly how that architecture renders.
Ready for clarity on your HαT?
Applications for the September 2026 cohort are open now and reviewed in the order received. Not ready? A free Ternary Brief on HαT is generated instantly, no charge.